Anti-NuMA antibodies in a psoriatic patient: considerations about clinical relevance and effect of infliximab treatment.
Antibodies against the nuclear mitotic spindle apparatus protein (NuMA) are infrequently detected during antinuclear antibodies testing on HEp-2 cells. In a series of 428 psoriatic patients anti-NuMA antibodies were found only in a patient, at a titer of 1:640, without any apparent clinical relevance. The significance of anti-NuMA is not yet known and is briefly reviewed, also in consideration of potential therapeutic implications. Although biologic drugs targeting tumor necrosis factor-alpha have been associated with the development of non-organ specific autoantibodies and rare reports of autoimmune phenomena, infliximab was well tolerated in this patient and caused no changes in autoantibody titers.
Tampoia
Marilina
M
Unit of Clinical Pathology, Policlinico, University of Bari, Bari, Italy.
Mastrandrea
Valentina
V
Cassano
Nicoletta
N
Vena
Gino Antonio
GA
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology; D006801:Humans; D000069285:Infliximab; D016547:Kinesins / Q000276:immunology*; D008297:Male; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D008941:Spindle Apparatus / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; D001324:Autoantigens; C470243:KIF11 protein, human; D000069285:Infliximab; D016547:Kinesins; C472181:efalizumab